# A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

Source: https://onco.cc/trials/nct06241846/  
OnCo record `nct06241846` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of YL201 in prostate cancer, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.

## Summary

A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC is a phase 2 interventional study registered as NCT06241846 by MediLink Therapeutics (Suzhou) Co., Ltd., with 100 participants planned, started 2024-02-22 and due to reach its primary completion in 2027-02. Interventions recorded: YL201 for Injection. Conditions listed: Metastatic Castration-resistant Prostate Cancer (mCRPC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06241846
- Phase: 2
- Setting: A Multicenter, Open-Label, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With Metastatic Castration-Resistant Prostate Cancer
- Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT06241846: https://clinicaltrials.gov/study/NCT06241846

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [YL201](https://onco.cc/drugs/yl201/)
- companies: [MediLink Therapeutics](https://onco.cc/companies/medilink/)

---
JSON: https://onco.cc/api/v1/entities/nct06241846.json